Aug 22, 2025
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a constellation of symptoms impacting both the autonomic nervous system and motor function. According to the National Organization for Rare Disorders (NORD), MSA affects between 15,000 and 50,000 individuals in the United Sta...
Read More...
Aug 12, 2025
FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...
Read More...
Jan 27, 2025
Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects the autonomic nervous system, motor function, and balance. It manifests through a combination of parkinsonism, autonomic dysfunction, and cerebellar ataxia, making it distinct from Parkinson’s disease despite overlapping...
Read More...
Nov 21, 2023
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper